The role of PCR in the diagnosis and management of CMV in solid organ recipients: What is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?

Transplantation

Volumn 63, Issue 2, 1997, Pages 275-279

  Abecassis, Michael M ^a,b   Koffron, Alan J ^a   Kaplan, Bruce ^a   Buckingham, Marguerite ^a   Muldoon, Joseph P ^a   Cribbins, Allan J ^a   Kaufman, Dixon B ^a   Fryer, Jonathan P ^a   Stuart, Joan ^a   Stuart, Frank P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; OKT 3; THYMOCYTE ANTIBODY; VIRUS DNA;

ARTICLE; CYTOMEGALOVIRUS INFECTION; EARLY DIAGNOSIS; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS INFECTION;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PANCREAS TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TRANSPLANTATION;

EID: 0030893372     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199701270-00017     Document Type: Article

References (31)

1. Brytting M, Sundqvist VA, Stalhanske P, Linde A, Wahren B. Cytomegalovirus DNA detection of an immediate early protein gene with nested primer oligonucleotides. J Virol Methods 1991; 32: 127.
2. Chou Q, Russel M, Birch DE, Raymond J, Bloch W. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. Nucleic Acids Res 1992; 20: 1717.
3. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350.
4. Abecassis MM, Jiang X, O'Neil ME, Bale JF Jr. Detection of murine cytomegalovirus (MCMV) DNA in skin using the polymerase chain reaction (PCR). Microbial Pathogenesis 1993; 15: 17.
5. Yedidag EN, Mueller KH, Kaufman DB, Stuart FP, Abecassis MM. Direct evidence for inhibition of the PCR with acyclovir-5′-triphosphate. Transplantation 1996; 62: 238.
6. Badley AD, Patel R, Portela DF, et al. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. J Infect Dis 1995; 173: 446.
7. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779.
8. Rondeau E, Bourgeon B, Peraldi MN, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858.
9. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
10. Drew WL, Miner RC, Busch DF, Gordon SM, Owen WE, Matthews TR, Buwhles WC, De Armond B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716.
11. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057.
12. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995; 123: 18.
13. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994; 120: 375.
14. Pillay D, Ali AA, Liu SF, Kops E, Sweny P, Griffiths PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 1993; 56: 103.
15. Van Dorp WT, Vlieger A, Jiwa NM, et al. The polymerase chain reaction, a sensitive and rapid technique for detecting cytomegalovirus infection after renal transplantation. Transplantation 1992; 54: 661.
16. Xu W, Sundqvist VA, Brytting M, Linde A. Diagnosis of cytomegalovirus infections using polymerase chain reaction, virus isolation and serology. Scand J Infect Dis 1993; 25: 311.
17. Urushibara N, Kwon KW, Takahashi TA, Sekiguchi S. Human cytomegalovirus DNA is not detectable with nested double polymerase chain reaction in health blood donors. Vox Sang 1995; 68: 9.
18. Ehrnst A, Einsele H. Towards standardizations of CMV DNA PCR assays. Scand J Infect Dis 1995; 99(suppl): 16.
19. Vinogradskaya GR, Goryshin IY, Berlin YA, Lanzov VA. Optimization of PCR-based diagnostics for human cytomegalovirus. J Virol Methods 1995; 53: 103.
20. Delgado R, Lumbreras C, Alba C, et al. Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients. J Clin Microbiol 1992; 30: 1876.
21. Peiris JS, Taylor CE, Main J, Graham K, Madeley CR. Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: the role of semiquantitative polymerase chain reaction (PCR). Nephrol Dial Transplant 1995; 10: 1198.
22. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993; 56: 867.
23. Einsele H, Ehninger G, Steidle M. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672.
24. Lee WT, Antoszewska H, Powell KF. Polymerase chain reaction in detection of CMV DNA in renal allograft recipients. Aust J Med 1992; 22: 249.
25. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815.
26. Grundy JE, Lui SF, Super M. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2: 132.
27. The TH, van den Berg AP, van Son WJ, et al. Monitoring for cytomegalovirus after organ transplantation: a clinical perspective. Transplant Proc 1993; 25(suppl 4): 5.
28. Drouet E, Colimon R, Michelson S, et al. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation. J Clin Microbiol 1995; 33: 389.
29. Rawal BK, Booth JC, Fernando S. Quantification of cytomegalovirus DNA in blood specimens from bone marrow transplant recipients by the polymerase chain reaction. J Virol Methods 1994; 47: 189.
30. Kulski JK. Quantitation of human cytomegalovirus DNA in leukocytes by end-point titration and duplex polymerase chain reaction. J Virol Methods 1994; 49: 195.
31. The TH, van den Berg AP, Harmsen MC. The cytomegalovirus antigenemia assay: a plea for standardization. Scand J Infect Dis 1995; 99(suppl): 25.